The MLCK-mediated alpha1-adrenergic inotropic effect in atrial myocardium is negatively modulated by PKCepsilon signaling

Br J Pharmacol. 2006 Aug;148(7):991-1000. doi: 10.1038/sj.bjp.0706803. Epub 2006 Jun 19.

Abstract

The present study examined the role of myosin light chain kinase (MLCK), PKC isozymes, and inositol 1,4,5-trisphosphate (IP(3)) receptor in the positive inotropic effect of alpha(1)-adrenergic stimulation in atrial myocardium. We measured inotropic effects of phenylephrine (0.3-300 microM) in isolated left atrial preparations (1 Hz, 37 degrees C, 1.8 mM Ca(2+), 0.3 microM nadolol) from male 8-week FVB mice (n=200). Phenylephrine concentration-dependently increased force of contraction from 1.5+/-0.1 to 2.8+/-0.1 mN (mean+/-s.e.m., n=42), which was associated with increased MLC-2a phosphorylation at serine 21 and 22 by 67% and translocation of PKCepsilon but not PKCalpha to membrane (+30%) and myofilament (+50%) fractions.MLCK inhibition using ML-7 or wortmannin right-shifted the concentration-response curve of phenylephrine, reducing its inotropic effect at 10 microM by 73% and 81%, respectively. The compound KIE1-1 (500 nM), an intracellularly acting PKCepsilon translocation inhibitor peptide, prevented PKCepsilon translocation and augmented the maximal inotropic effect of phenylephrine by 40%. In contrast, inhibition of Ca(2+)-dependent PKC translocation (KIC1-1, 500 nM) had no effect. Chelerythrine, a PKC inhibitor, decreased basal force without changing the inotropic effect of phenylephrine. The IP(3) receptor blocker 2-APB (2 and 20 microM) concentration-dependently decreased basal force, but did not affect the concentration-response curve of phenylephrine. These results indicate that activation of MLCK is required for the positive inotropic effect of alpha(1)-adrenergic stimulation, that the Ca(2+)-independent PKCepsilon negatively modulates this effect, and that PKCalpha and IP(3) receptor activation is not involved.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Calcium / metabolism
  • Calcium / physiology
  • Cardiotonic Agents / pharmacology
  • Heart / drug effects*
  • Heart Atria
  • In Vitro Techniques
  • Inositol 1,4,5-Trisphosphate / pharmacology
  • Isoproterenol / pharmacology
  • Male
  • Mice
  • Myocardial Contraction / drug effects*
  • Myosin-Light-Chain Kinase / physiology*
  • Phenylephrine / pharmacology
  • Phosphorylation
  • Protein Kinase C-epsilon / physiology*
  • Receptors, Adrenergic, alpha-1 / physiology*
  • Sarcoplasmic Reticulum / drug effects
  • Sarcoplasmic Reticulum / metabolism
  • Signal Transduction / physiology*
  • Subcellular Fractions / drug effects
  • Tetradecanoylphorbol Acetate / pharmacology

Substances

  • Adrenergic beta-Agonists
  • Cardiotonic Agents
  • Receptors, Adrenergic, alpha-1
  • Phenylephrine
  • Inositol 1,4,5-Trisphosphate
  • Protein Kinase C-epsilon
  • Myosin-Light-Chain Kinase
  • Isoproterenol
  • Tetradecanoylphorbol Acetate
  • Calcium